Compare Sanofi SA (SNY) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Yum! Brands, Inc. — how do they compare? Sanofi SA trades at $43.6 (market cap $104.30B), while Yum! Brands, Inc. trades at $150 (market cap $39.50B). The key difference: Sanofi SA is far larger — about 2.6× Yum! Brands, Inc.'s market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| SNY | YUM | |
|---|---|---|
Market Cap | $104.30B | $39.50B |
Sector | Health | Consumer Cyclical |
52-Week High | $52.34 | $168.16 |
52-Week Low | $41.33 | $138.21 |
Enterprise Value | $124.19B | $51.10B |
Dividend Yield | 5.55% | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
YUM trades at $150.15, up 3.32% in the past 24 hours, with a bearish technical signal from moving averages but neutral oscillators. Recent earnings show a Q2 2026 beat with EPS of $1.62 versus $1.57 expected, while revenue grew to $8.21B in 2025. The company completed the sale of Pizza Hut China for $1.2B in August 2026, aiming to streamline operations and reduce debt. Cash flow from operations improved to $2.01B in 2025, supporting a dividend payment of $0.75 per share.
The outlook is mixed, with analyst consensus leaning hold (56.87%) but a price target of $174.60 implying 16% upside. Risks include ongoing legal investigations and a parasite outbreak impacting Taco Bell sales, though management reports recovery. Debt remains high at $11.25B long-term, but the debt-to-asset ratio improved to 143.49 in 2025. Execution on digital growth and brand focus post-Pizza Hut sale are key to unlocking value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
